132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment
The National Lung Cancer Audit (NLCA) reported in November 2023 that 79% of patients with non-small cell lung cancer (NSCLC) with stage I or II disease and a performance status (PS) of 0-2 received curative intent treatment (audit standard ≥80%), and 60% of patients with NSCLC stage IIIA, PS 0-2, received curative intent treatment. Furthermore, 61% of patients with NSCLC stage IIIB–IV, PS0-1 received systemic anticancer treatment (audit standard ≥65%). To compare against national standards, a retrospective review was performed. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Karen Clayton, Larissa Griffiths, Joanna Gallagher, Bethan Clayton Tags: Other Source Type: research
133 Review of Advanced Lung cancer treatment in relation to the NLCA report
Lung cancer has the lowest fiver year survival. Prognosis is far worse in people with advanced stage. National Lung cancer Audit 2023 (data period 2021) results showed that only 61% patients with non-small cell lung cancer (stage IIIB - IV, PS 0-1) had systemic cancer treatment. We aim to see if it was a similar trend for the year 2022 and to explore the reasons for any low treatment rate. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lokesh Kovvuri, Viktoria Oakden, Shahul Leyakathali Khan Tags: Other Source Type: research
134 Lung cancer patients ’ views, experiences of treatment and communications preferences – findings from the Global Lung Cancer Coalition's fourth annual global survey
In 2023, the Global Lung Cancer Coalition (GLCC), a partnership of 43 non-government patient organisations across 30 countries, ran its fourth annual global patient experience survey to explore patients ’ involvement in decision-making and preferred methods of contact with their treatment teams. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Aoife McNamara, Jackie Fenemore, Jesme Fox, Elizabeth Beck Tags: Other Source Type: research
135 The Impact of the Electronic Patient Record on Completion and Uploading of the Holistic Needs Assessment in Lung Cancer patients
The Holistic Needs Assessment (HNA) was recommended by the UK NHS Cancer Five Year Strategy 2015 for patients with cancer at time of diagnosis, treatment change and completion1. It is a structured assessment of aspects of patients ’ lives to find concerns, producing a care plan to address any issues. HNA completion and implementation is variable and there is little research on its use in lung cancer. Generally the CNS team issue questionnaires, assessing if action is required. Our trust implemented a new electronic patient record so we used this opportunity to assess if our Unit's completion rates of the HNA could improv...
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Lydia Gabriel, Jaishree Bhosle, Michael Davidson, Anna Minchom, Charlotte Milner-Watts, Arnold Dela-Rosa, Lisa Parish, Karon Payne, Sarah Sarker, Joanna Vick, Mary O'Brien Tags: Other Source Type: research
136 Supporting the wellbeing of oncodriven lung cancer patients online: a qualitative study
Oncodriven lung cancer (OLC) patients experience elevated levels of psychological distress, however there is a dearth of research into the wellbeing needs of this patient group. Furthermore, few receive adequate mental health support, and many are unaware of what wellbeing-related support is available. As quality of life is related to treatment adherence and outcomes, it is imperative we understand the needs of these patients, and establish ways to better support them. eHealth offers a potentially scalable solution to improving awareness of and access to support, and has been shown to be efficacious and acceptable for an a...
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Virginia Harrison, Katie Jones, Caroline Hyde, Deepa Doshi, Angela Terry, Debra Montague Tags: Other Source Type: research
137 A Randomised Controlled Feasibility Trial of Surgery versus No Surgery as Part of Multi-Modality Treatment in Stage III – N2 Non-Small Cell Lung Cancer
Optimal treatment for stage III-N2 non-small cell lung cancer (NSCLC) requires surgical or non-surgical multi-modality treatment. Studies have failed to demonstrate superiority of either approach. Evidence exploring patient/carer quality of life across the different treatment pathways is limited. Data describing the N2 population in the United Kingdom (UK), and the proportion of patients with resectable disease is also limited. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Sally Taylor, Melissa Stanworth, Ashleigh Ward, Emily Harris, Selina Tsim, Neal Navani, David Baldwin, Ian Woolhouse, John Edwards, Seamus Grundy, Sarah Rhodes, Nathan Burnside, Fiona Blackhall, Corinne Faivre-Finn, Janelle Yorke, Matthew Evison Tags: Other Source Type: research
138 Therapeutic Radiographer Led Thoracic SABR services: Optimisation of skill mix in two large northern cancer centres
The UK has a 15% shortfall of clinical oncologists, with 54% clinical oncology vacancies open for over a year. It is projected to rise by 25% in 2027. Patients experience delays in their radiotherapy treatment, in half of cancer centres. With, 1 in 4 centres experiencing this each week (the Royal college of radiologists census, 2022). Demand for SABR will continue to increase, with the announcement of the national targeted lung cancer screening programme. This, highlights the need for departments to expand use of skill mix. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Rebecca Pickles, Rachael Wooder Tags: Radiotherapy Source Type: research
139 MR-guided adaptive stereotactic ablative body radiotherapy (MRgSABR) in thoracic tumours
Stereotactic-ablative body radiotherapy (SABR) is an effective modality for early-stage lung cancer and thoracic metastases. However, target motion, ultra-central/central location and respiratory comorbidity compromise optimal dose delivery. MR-guided-SABR (MRgSABR) provides real-time tracking and daily-adaptation, allowing higher doses compared to conventional-SABR. This may improve local control (LC), progression-free survival (PFS), and overall survival (OS) while applying an isotoxic approach. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Elena Moreno-Olmedo, Ben George, David Woolf, John Conibear, Andy Gaya, Kasia Owczarczyk, Luis Aznar, Joss Adams, Veni Ezhil, Timothy Sevitt, Peter Dickinson, Kevin Franks, Alex Martin, Philip Camilleri, James Good, Crispin Hiley Tags: Radiotherapy Source Type: research
140 How many locally advanced NSCLC patients receive Durvalumab and what are the limiting factors?
Durvalumab is recommended for treatment of inoperable stage 3 non-small cell lung cancers (NSCLC), in PDL1 positive patients who have not progressed on platinum-based chemo-radiation (cCRT). Additional factors can prevent or limit the use of Durvalumab. The aim of this retrospective audit was to explore how many stage 3 NSCLC patients treated in our department received Durvalumab, how many cycles they received, and to explore why Durvalumab was either not offered or discontinued. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Catherine Sharma, Abigail Pascoe Tags: Radiotherapy Source Type: research
141 Don't be ageist: considering the use of multimodality treatment in older adults with unresectable locally advanced Non-Small Cell Lung Cancer (NSCLC)
This study provides a real-world evaluation of chemoradiotherapy (+/- durvalumab) in an elderly and co-morbid patient cohort. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Oliver Coen, Nathaniel Hatton, Katy Clarke, Peter Dickinson, Kevin Franks, Chandran Nallathambi, Christine Podesta, Fei Sun, Mark Teo, Pooja Jain Tags: Radiotherapy Source Type: research
142 Survival outcomes for concurrent chemo-radiotherapy (cCRT) patients in stage III lung cancer: Real world data from the northern centre for cancer care (NCCC) utilising 2 regimes.
Standard of care for stage-III un-resectable disease is cCRT. NCCC reviewed cCRT practices in 2020, introducing a stage-III MDT to optimise treatment pathways, with the aim of expanding inclusion of patients to reflect real-life local population. A concurrent regime of weekly carboplatin/paclitaxel (carbo/taxol) with 60 –66 Gy/ 2 Gy fractions was introduced for PS0-2 patients, alongside preexisting concurrent Cisplatin/Vinorelbine (Cis/Vin) with 55 Gy hypo-fractionated regime for PS0-1 patients. Adjuvant-durvalumab immunotherapy in appropriate patients was adopted. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Rebecca Pickles, EIeanor Smith, AIexander Stamp, Fiona E Mcdonald, Adam Hassani, Alistair Greystoke Tags: Radiotherapy Source Type: research
143 Using ProKnow to explore the incidence of radiation pneumonitis in relation to GTV size in Stage III Non-Small Cell Lung Cancer (NSCLC) concurrent Chemoradiotherapy (cCRT) patients and its impact on survival. A Pilot Study
Radiation oncology generates a wealth of data within planning systems, during on-treatment review and patient follow-up, but unlocking this “big data” can be laborious. Comparing or sharing data across many departments is more challenging due to a lack of a national database and information governance concerns. ProKnow provides the opportunity for departments to audit their practice, and eventually collaborate more widely with other providers. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: AIexander Stamp, Rebecca Pickles, Samantha Warren, EIeanor Smith, Fiona E McDonald, Adam Hassani, Helen Turnbull Tags: Radiotherapy Source Type: research
144 Reducing the risk of death from PJP after radical lung cancer radiotherapy – second round QI intervention updated with early outcome data
Pneumocysitis Jirovecii Pneumonia (PJP) is an opportunistic infection with a high mortality rate. Radical radiotherapy (RR) for lung cancer is associated with a 4% risk of death from PJP. National guidelines recommend consideration of prophylaxis for PJP (prop-PJP) in patients at high risk. Risk factors include low nadir lymphocyte count (NLC) and a prolonged course of high dose steroids (HDS). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Martin Leer, Jin Tee, Karen Tumelty, Cathryn Crockett, Jolyne O'Hare, Gerard G Hanna, Jonathan McAleese, Linda Young Tags: Radiotherapy Source Type: research
145 Establishing a National Therapeutic Lung Cancer Radiographer Group (TLC Rads)
In response to workforce shortages and to meet capacity demands in a service with increasingly technical complexity, therapeutic radiographers have developed a range of expert clinical and research skills and now perform tasks that blur the traditional boundaries between radiographer and Clinical Oncologist. However, Radiographers that have lung radiotherapy at the core of their role remain scarce nationally. This is despite being perfectly placed to provide highly specialised services that improve outcomes in lung oncology. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Emma Wingate, Rebecca Pickles, Lindsey White, Lindsey White, Karen Moore, Lynn Bell, Michelle Bewley, David Finn, Stephanie Hatcliffe, Rachel Kirby, Caroline Maguire, Deborah McCrimmon, Matthew Roughley, Catherine Sharma, Alex Stamp, Rachel Wooder Tags: Radiotherapy Source Type: research
146 Using Electronic Patient-Reported Outcome Measures (ePROMs) to Monitor Symptoms and Quality of Life for Patients with Lung Cancer Undergoing Radiotherapy. A Pilot Study
This study used electronic patient-reported outcomes measures (ePROMs) to monitor radiotherapy toxicity at several additional timepoints during and after radiotherapy. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Thitikorn Nuamek, Sarah Bowen Jones, Peggy Adwoa Nuamah Kwateng, Danya Abdulwahid, Claire Barker, Kathryn Banfill, Neil Bayman, Clara Chan, Joanna Coote, Margaret Harris, Jennifer King, Laura Pemberton, Hamid Younus Sheikh, David Woolf, Janelle Yorke, Jam Tags: Radiotherapy Source Type: research
